Literature DB >> 27823684

Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.

Michael Valentino1, Jad Al Danaf2, Andrew Panakos2, Loheetha Ragupathi2, Danielle Duffy3, David Whellan3.   

Abstract

BACKGROUND: The 2013 American College of Cardiology/American Heart Association cholesterol management guidelines represented a paradigm shift from the National Cholesterol Education Program Adult Treatment Panel III guidelines, replacing low-density lipoprotein cholesterol targets with a risk assessment model to guide statin therapy. Our objectives are to compare provider prescription of high-intensity statin therapy in patients hospitalized with acute coronary syndrome (ACS) or cerebrovascular accident (CVA) before and after the publication of the 2013 cholesterol guidelines, determine potential predictors of high-intensity statin utilization, and identify targets for improvement in cardiovascular risk reduction among these high-risk populations.
METHODS: A single-center retrospective cohort study of 695 patients discharged with a diagnosis of ACS or CVA in the 6months before (n=359) and after (n=336) the release of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. Patient characteristics were compared using analysis of variance and χ2 tests. Multivariable logistic regression models were used to assess clinical predictors of provider utilization of high-intensity statins.
RESULTS: After the 2013 cholesterol guidelines, the rate of prescribing high-intensity statins was greater for statin-naïve patients compared with those already on statin therapy (odds ratio [OR]0.51, P=.02). Prescription of high-intensity statins was higher for patients with ACS compared with CVA (OR 8.4, P<.001-pre-2013 guidelines; OR 4.5, P<.001-post-2013 guidelines). Prescription of high-intensity statins steadily improved over the study period, significantly among patients with CVA (P<.001).
CONCLUSIONS: Physicians were more likely to prescribe high-intensity statins in statin-naïve patients as compared with intensifying existing statin therapy, and their prescription pattern was lower after CVA vs ACS.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27823684     DOI: 10.1016/j.ahj.2016.07.024

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions.

Authors:  Susan H Boklage; Elisabetta Malangone-Monaco; Lorena Lopez-Gonzalez; Yao Ding; Caroline Henriques; Joseph Elassal
Journal:  Cardiovasc Drugs Ther       Date:  2018-06       Impact factor: 3.727

Review 2.  Creatine as a Candidate to Prevent Statin Myopathy.

Authors:  Maurizio Balestrino; Enrico Adriano
Journal:  Biomolecules       Date:  2019-09-17

3.  Gaps in Dyslipidemia Care Among Working-Aged Individuals With Employer-Sponsored Health Care.

Authors:  Dov Shiffman; Judy Z Louie; James J Devlin; Joshua W Knowles; Michael J McPhaul
Journal:  J Am Heart Assoc       Date:  2020-04-22       Impact factor: 5.501

4.  Association Between Statin Use and Exacerbation of Chronic Obstructive Pulmonary Disease Among Patients Receiving Corticosteroids.

Authors:  Wu-Chien Chien; Kwua-Yun Wang; Yi-Jen Huang; Senyeong Kao; Li-Ting Kao; Chih-Feng Chian; Chi-Hsiang Chung
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-05

5.  Rosuvastatin protects against oxidized low‑density lipoprotein‑induced endothelial cell injury of atherosclerosis in vitro.

Authors:  Jianan Geng; Huali Xu; Xiaofeng Yu; Guoliang Xu; Hongyan Cao; Guangzhu Lin; Dayun Sui
Journal:  Mol Med Rep       Date:  2018-11-19       Impact factor: 2.952

6.  Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease.

Authors:  Glenn T Gobbel; Michael E Matheny; Ruth R Reeves; Julia M Akeroyd; Alexander Turchin; Christie M Ballantyne; Laura A Petersen; Salim S Virani
Journal:  Am J Prev Cardiol       Date:  2021-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.